Guggenheim analyst Yatin Suneja reiterated a Buy rating and $175.00 price target on Abivax (NASDAQ: ABVX)The analyst commented, "Key highlights ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE